GLP-1 medicines: who gets them and who is left out
New generic semaglutide in India costs as little as Rs 325 a week, so far more people can afford it now. But rural clinics, thin insurance, and pricey imported tirzepatide still leave many people behind.
GLP-1 medicines help people with diabetes and obesity. They work well. But they have been very costly. For years, only richer people could buy them. That story is now changing in India. This article is about fairness. Who can get these medicines? Who is still left behind? We will look at the real prices, the real gaps, and what you can do.
The big global access problem
Around the world, GLP-1 medicines are hard to get. A big study looked at 99 countries. It found about 27% of adults qualify for these medicines. That is more than 1 in 4 people. Most of them live in poorer countries. The study says almost four-fifths of the people who need GLP-1 medicines live in low- and middle-income countries. But these medicines cost a lot. The World Health Organization (WHO) says high prices keep people from getting them. In 2025, WHO added GLP-1 medicines to its Essential Medicines List. This list tells countries which drugs are most important. WHO hopes this pushes prices down so more people can afford them.
Branded vs generic semaglutide in India (March 2026)
In March 2026, the semaglutide patent ended in India. Six Indian companies launched their own generic versions at once. Prices fell fast. The table shows the monthly cost for a starting dose. This is the biggest price drop in GLP-1 history in India.
Only rich people can use GLP-1 medicines.
mostly falseMostly false in India now — but partly true for tirzepatide and for rural access. Generic semaglutide changed the game. A Glenmark leader said, 'With Glipiq, we are setting a new benchmark in affordability for GLP-1 therapy, with weekly treatment starting at Rs 325.' So real semaglutide is no longer just for the rich in India. But imported tirzepatide (Mounjaro) is still costly. And village families still face clinic and doctor shortages. So the claim is mostly false for semaglutide in cities, but still partly true for rural India and for newer GLP-1 medicines.
Rural India is still left behind
Cheaper medicine is a huge win. But a low price only helps if you can reach a doctor and a clinic. India has a big rural-urban gap in diabetes care. A 2023 study in JAMA Internal Medicine looked at diabetes care across India. It found that diagnosis and treatment were higher in cities, in older people, and in wealthier homes. It said there were 'rural-urban differences' and big gaps between districts. So a person in a village may still struggle to get a proper prescription, lab tests, or follow-up care, even if the medicine itself is cheap. Specialist doctors (endocrinologists) are mostly in big cities. This is the fairness gap that remains.
Affordable, legal options in India
The bottom line
Real semaglutide is now affordable in India. That is a genuine fairness win. But access is still uneven. Rural families, poor insurance, and pricey tirzepatide keep many people out. The job is not done. We should push for more doctors, more clinics, and lower prices for every GLP-1 medicine, so no one who needs help is left behind.